JP2015513083A5 - - Google Patents

Download PDF

Info

Publication number
JP2015513083A5
JP2015513083A5 JP2014558737A JP2014558737A JP2015513083A5 JP 2015513083 A5 JP2015513083 A5 JP 2015513083A5 JP 2014558737 A JP2014558737 A JP 2014558737A JP 2014558737 A JP2014558737 A JP 2014558737A JP 2015513083 A5 JP2015513083 A5 JP 2015513083A5
Authority
JP
Japan
Prior art keywords
psma
agent
imaging
adenocarcinoma
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014558737A
Other languages
English (en)
Japanese (ja)
Other versions
JP6501524B2 (ja
JP2015513083A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/000045 external-priority patent/WO2013126147A2/en
Publication of JP2015513083A publication Critical patent/JP2015513083A/ja
Publication of JP2015513083A5 publication Critical patent/JP2015513083A5/ja
Application granted granted Critical
Publication of JP6501524B2 publication Critical patent/JP6501524B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014558737A 2012-02-24 2013-02-22 Psma上昇により致死性前立腺癌が同定される Expired - Fee Related JP6501524B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261602900P 2012-02-24 2012-02-24
US61/602,900 2012-02-24
PCT/US2013/000045 WO2013126147A2 (en) 2012-02-24 2013-02-22 Elevated psma identifies lethal prostate cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019050913A Division JP2019144254A (ja) 2012-02-24 2019-03-19 Psma上昇により致死性前立腺癌が同定される

Publications (3)

Publication Number Publication Date
JP2015513083A JP2015513083A (ja) 2015-04-30
JP2015513083A5 true JP2015513083A5 (cg-RX-API-DMAC10.html) 2016-03-31
JP6501524B2 JP6501524B2 (ja) 2019-04-17

Family

ID=49003541

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014558737A Expired - Fee Related JP6501524B2 (ja) 2012-02-24 2013-02-22 Psma上昇により致死性前立腺癌が同定される
JP2019050913A Pending JP2019144254A (ja) 2012-02-24 2019-03-19 Psma上昇により致死性前立腺癌が同定される

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019050913A Pending JP2019144254A (ja) 2012-02-24 2019-03-19 Psma上昇により致死性前立腺癌が同定される

Country Status (6)

Country Link
US (2) US20130225541A1 (cg-RX-API-DMAC10.html)
EP (2) EP3064945A1 (cg-RX-API-DMAC10.html)
JP (2) JP6501524B2 (cg-RX-API-DMAC10.html)
CA (1) CA2865282A1 (cg-RX-API-DMAC10.html)
HK (1) HK1205788A1 (cg-RX-API-DMAC10.html)
WO (1) WO2013126147A2 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2865774A1 (en) * 2012-02-28 2013-09-06 Cornell University Psma as a biomarker for androgen activity in prostate cancer
EP4636783A3 (en) * 2016-10-27 2025-12-24 Progenics Pharmaceuticals, Inc. Network for medical image analysis, decision support system, and related graphical user interface (gui) applications
EP3571221A2 (en) 2017-01-20 2019-11-27 Juno Therapeutics GmbH Cell surface conjugates and related cell compositions and methods
MX2019012017A (es) 2017-04-07 2020-02-12 Juno Therapeutics Inc Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
US12602772B2 (en) 2018-01-08 2026-04-14 Progenics Pharmaceuticals, Inc. Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination
JP7568628B2 (ja) 2019-01-07 2024-10-16 エクシーニ ディアグノスティクス アーべー プラットホーム非依存の全身画像セグメント化のためのシステムおよび方法
CA3136127A1 (en) 2019-04-24 2020-10-29 Progenics Pharmaceuticals, Inc. Systems and methods for automated and interactive analysis of bone scan images for detection of metastases
US11900597B2 (en) 2019-09-27 2024-02-13 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
US12417533B2 (en) 2019-09-27 2025-09-16 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
AU2021244617A1 (en) 2020-03-26 2022-11-10 Migdalia FORT Ultraviolet radiation treatments
US11721428B2 (en) 2020-07-06 2023-08-08 Exini Diagnostics Ab Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions
US12597127B2 (en) 2021-10-08 2026-04-07 Exini Diagnostics Ab Systems and methods for automated identification and classification of lesions in local lymph and distant metastases
CN119791845B (zh) * 2025-01-03 2026-05-08 北京大学第一医院(北京大学第一临床医学院) 一种降低前列腺根治性切除术后切缘阳性的治疗设备

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2436408A1 (en) * 2001-02-07 2002-12-12 Beth Israel Deaconess Medical Center Modified psma ligands and uses related thereto
CA2447695C (en) * 2001-06-01 2015-02-24 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
ES2314272T3 (es) * 2003-01-10 2009-03-16 Millennium Pharmaceuticals, Inc. Metodos para el diagnostico y el tratamiento del cancer.
US7560531B2 (en) * 2003-05-29 2009-07-14 Diadexus, Inc. Cln101 antibody compositions and methods of use alone and in combination with prostate specific antigen and other cancer markers
WO2008050255A2 (en) * 2006-10-25 2008-05-02 Koninklijke Philips Electronics N. V. Contrast agents for detecting prostate cancer
WO2009046294A2 (en) * 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
WO2009127046A1 (en) * 2008-04-14 2009-10-22 Proscan Rx Pharma Inc. Prostate specific membrane antigen antibodies and antigen binding fragments
CN102308212A (zh) * 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
JP5906090B2 (ja) * 2009-02-17 2016-04-20 コーネル・リサーチ・ファンデーション・インコーポレイテッドCornell Research Foundation, Incorporated 癌の診断のための方法およびキットならびに治療価の推定
US8772226B2 (en) * 2009-03-17 2014-07-08 The Johns Hopkins University Methods and compositions for the detection of cancer

Similar Documents

Publication Publication Date Title
Alam et al. Emerging intraoperative imaging modalities to improve surgical precision
Giesel et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
Rowe et al. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges
Kanoun et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma
Mohs et al. A Handheld spectroscopic device for in vivo and intraoperative tumor detection: contrast enhancement, detection sensitivity, and tissue penetration
Servagi-Vernat et al. A prospective clinical study of 18 F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy
Zangheri et al. PET/CT and breast cancer
JP6501524B2 (ja) Psma上昇により致死性前立腺癌が同定される
Udovicich et al. 68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: current state and future trends
Bailey et al. Performance of 68Ga-PSMA PET/CT for prostate cancer management at initial staging and time of biochemical recurrence
Delouya et al. 18F-FDG-PET imaging in radiotherapy tumor volume delineation in treatment of head and neck cancer
Basu et al. Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment
Lee et al. Clinical implications of initial FDG-PET/CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
Tang et al. Preclinical imaging evaluation of novel TSPO-PET ligand 2-(5, 7-Diethyl-2-(4-(2-[18F] fluoroethoxy) phenyl) pyrazolo [1, 5-a] pyrimidin-3-yl)-N, N-diethylacetamide ([18F] VUIIS1008) in glioma
Abgral et al. Prognostic evaluation of percentage variation of metabolic tumor burden calculated by dual‐phase 18FDG PET‐CT imaging in patients with head and neck cancer
Kurihara et al. Molecular imaging using PET for breast cancer
Zhou et al. Targeted fluorescent imaging of a novel FITC-labeled PSMA ligand in prostate cancer
Estorch et al. Future challenges of multimodality imaging
Wáng et al. Molecular imaging: from bench to clinic
Lewis et al. [18f] fluoroethyltyrosine-induced cerenkov luminescence improves image-guided surgical resection of glioma
Zhao et al. Somatostatin receptor imaging with [68Ga] Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma
Bouchelouche et al. Advances in imaging modalities in prostate cancer
Luo et al. Harnessing the power of molecular imaging for drug discovery and development
Conti New prospects for PET in prostate cancer imaging: a physicist's viewpoint
Netzer et al. To operate or to radiate: the added value of the maximal standardized uptake value in PET–FDG in cervical cancer patients